

Pruritus - Pipeline Insight, 2021

<https://marketpublishers.com/r/P64DA88F07CEN.html>

Date: June 2021

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: P64DA88F07CEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Pruritus - Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pruritus Understanding

Pruritus: Overview

Pruritus, also known as itching is defined as an unpleasant sensation that provokes the desire to scratch. Beyond an itching sensation, symptoms of pruritus can include redness, blisters, dry, cracked and scaly skin. Itch has been categorized into the following four classifications: cutaneous, neuropathic, neurogenic, and psychogenic. Pruritus, or itch, is most commonly associated with a primary skin disorder such as xerosis, atopic dermatitis, drug eruption, urticaria, psoriasis, arthropod assault, mastocytosis, dermatitis herpetiformis, or pemphigoid. Diagnostic testing is directed by the clinical evaluation and may include a complete blood count and measurement of thyroid-stimulating hormone, serum bilirubin, alkaline phosphatase, serum creatinine, and blood urea nitrogen levels. The treatment of pruritus includes topical agents, systemic agents, physical modalities, and non-pharmacological treatments.

'Pruritus - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritus pipeline landscape is provided which includes the disease overview and Pruritus treatment guidelines. The assessment part of the report embraces, in depth Pruritus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Pruritus.

Pruritus Emerging Drugs Chapters

This segment of the Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pruritus Emerging Drugs

Difelikefalin: Cara Therapeutics

Difelikefalin is a small peptide molecule based peripheral kappa opioid receptor agonist. In March 2021, FDA has accepted for priority review the New Drug Application (NDA) for difelikefalin (Korsuva), for the treatment of moderate to severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is 23 August 2021. The drug is also in clinical studies for the management of pain and renal failure.

BLU-5937: BELLUS Health

BLU-5937 is an orally available small molecule based P2X3 antagonist. The drug is in Phase II clinical developmental studies for the treatment of chronic cough and chronic pruritus.

Further product details are provided in the report..

Pruritus: Therapeutic Assessment

This segment of the report provides insights about the different Pruritus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pruritus

There are approx. 40+ key companies which are developing the therapies for Pruritus. The companies which have their Pruritus drug candidates in the most advanced stage, i.e. Preregistration include, Cara Therapeutics.

Phases

DelveInsight's report covers around 40+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pruritus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pruritus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritus drugs.

Pruritus Report Insights

Pruritus Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pruritus Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pruritus drugs?

How many Pruritus drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritus?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers

and acquisitions, licensing activities related to the Pruritus therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pruritus and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Cara Therapeutics

BELLUS Health

Regeneron

Maruho

Trevi Therapeutics

AbbVie

Lumosa Therapeutics

9 Meters Biopharma

Atridia

Suzhou Connect Biopharmaceuticals

Avior Bio

Saniona

DermaXon

Akari Therapeutics

Key Products

Difelikefalin

BLU-5937

Dupilumab

M-5250

T 111

Onabotulinum toxin A

LT-5001

RDD1609

SHR-0410

CBP-174

AV-104

SAN-711

DX-412

Votucalis

Contents

- Introduction
- Executive Summary
- Pruritus: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Pruritus – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Pruritus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Pruritus Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Preregistration)
 - Comparative Analysis
- Difelikefalin: Cara Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report..
- Mid Stage Products (Phase II)
 - Comparative Analysis
- BLU-5937: BELLUS Health
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report..

Early Stage Products (Phase I/II)

Comparative Analysis

LT-5001: Lumosa Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical/Discovery Stage Products

Comparative Analysis

SAN-711: Saniona

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Pruritus Key Companies**Pruritus Key Products****Pruritus- Unmet Needs****Pruritus- Market Drivers and Barriers****Pruritus- Future Perspectives and Conclusion****Pruritus Analyst Views****Pruritus Key Companies****Appendix**

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Pruritus
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Pruritus
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Pruritus - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P64DA88F07CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P64DA88F07CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970